绥美凯国内怎么买？

It is a film-coated tablet that appears white or off-white after removing the coating. It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B*5701 allele, he should not take products containing abacavir. For adults and adolescents (weighing not less than 40kg), the recommended dosage of SuimeiKai is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. Today we will find out how to buy Suimeikai in China?

Suimeikai, produced by the Indian company Emcure, comes in a box of 30 tablets and sells for about RMB 1,000. If patients choose this highly cost-effective Indian Suimeikan, they can go to India to buy it in person, but it is best to obtain it through domestic professional overseas medical service institutions.

Suimeikai was approved by the FDA on August 27, 2014. On January 20, 2018, ViiV, a joint venture of GlaxoSmithKline, launched the first complete antiviral treatment program with dolutegravir (also known as DTG in English) as the core drug - Suimeike in China. This is also the first complete single-pill compound treatment program in the field of HIV treatment in China. 

As a compound preparation, Suimeikai can achieve the effect of combined medication by taking one drug. The drug's antiviral effect is similar to that of tenofovir, but it has less damage to mitochondria, thereby reducing fat consumption, pancreatitis, neuritis, lactic acidosis and other adverse reactions. Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle). Existing research shows that one year (48 weeks) after HIV-infected patients were treated with TRIUMEQ, the viral load of 93% of the infected patients became negative. Suimeikai has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients.

The above is the content of purchasing channels, I hope it can help you!